ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.07
0.46%
US Tech 100
17,244.00
1.57%
S&P 500
5,099.96
1.02%
US Dollar vs CAD
1.36805
0.00%
Bitcoin
63,530.00
0.19%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Allogene Therapeutics Inc (ALLO)

  7. Allogene Therapeutics Inc (ALLO) News

ALLO Allogene Therapeutics Inc

2.91
0.055 (1.93%)
Apr 26 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Allogene Therapeutics Inc ALLO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.055 1.93% 2.91 23:00:03
Open Price Low Price High Price Close Price Previous Close
2.87 2.75 2.93 2.89 2.855
more quote information »

Recent News

Date Time Source Heading
4/26/202407:30GLOBEAllogene Therapeutics Awarded Grant from the California..
4/09/202407:30GLOBEAllogene Therapeutics Announces Q2 Investor Conference..
3/14/202415:05GLOBEAllogene Therapeutics Reports Fourth Quarter and Full Year..
3/12/202407:30GLOBEAllogene Therapeutics and Arbor Biotechnologies Announce..
3/05/202407:30GLOBEAllogene Therapeutics to Report Fourth Quarter and Full Year..
2/28/202407:30GLOBEAllogene Therapeutics Announces Participation in the 44th..
2/16/202407:30EDGAR2Form 8-K - Current report
2/16/202407:30GLOBEAllogene Therapeutics to Restate Previously Filed Financial..
1/31/202416:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/24/202416:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/22/202415:11EDGAR2Form 144 - Report of proposed sale of securities
1/16/202415:05GLOBEAllogene Therapeutics Announces Participation in Upcoming..
1/05/202407:00EDGAR2Form 8-K - Current report
1/04/202415:15GLOBEAllogene Therapeutics and Foresight Diagnostics Announce..
1/04/202415:05GLOBEAllogene Therapeutics Announces 2024 Platform Vision to..
1/03/202415:05GLOBEAllogene Therapeutics to Host Conference Call Previewing its..
12/20/202315:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/19/202314:46EDGAR2Form 8-K - Current report
12/18/202315:17EDGAR2Form 144 - Report of proposed sale of securities
12/09/202311:00GLOBEAllogene Therapeutics Presents Comprehensive Safety Data of..
12/01/202307:30GLOBEAllogene Therapeutics Announces Participation in December..
11/03/202311:00GLOBEAllogene Therapeutics Presents Preclinical Data on a Novel..
11/02/202315:41EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11/02/202315:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/02/202315:03EDGAR2Form 8-K - Current report
11/02/202315:02GLOBEAllogene Therapeutics Reports Third Quarter 2023 Financial..
11/02/202308:00GLOBEAllogene Therapeutics Announces Poster Presentations at the..
10/30/202307:30GLOBEAllogene Therapeutics Announces Participation in November..
10/26/202307:30GLOBEAllogene Therapeutics to Report Third Quarter 2023 Financial..
10/17/202315:34EDGAR2Form 8-K/A - Current report: [Amend]
10/16/202307:31EDGAR2Form 8-K - Current report
10/16/202307:30GLOBEAllogene Therapeutics Appoints Geoffrey Parker as Chief..
9/27/202308:09GLOBEAllogene Therapeutics Announces Three Poster Presentations..
9/05/202307:30GLOBEAllogene Therapeutics Announces Participation in September..
8/14/202318:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/14/202318:28EDGAR2Form 3 - Initial statement of beneficial ownership of..
8/14/202307:30GLOBEAllogene Therapeutics Appoints Earl Douglas as General..
8/09/202315:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/07/202316:15EDGAR2Form 144 - Report of proposed sale of securities
8/02/202315:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/02/202315:04EDGAR2Form 8-K - Current report
8/02/202315:02GLOBEAllogene Therapeutics Reports Second Quarter 2023 Financial..
7/26/202307:30GLOBEAllogene Therapeutics to Report Second Quarter 2023..
7/11/202305:06VWEthereum Blockchain Game Pikamoon Raises $3.6m, Final ICO..
7/10/202309:44VWMassive Gaming Celebrates Global Launch of House of..
7/10/202304:52VWWOW EARN Wallet Offers One-Stop Shop Features, Now Available..
7/10/202304:02VWSwaap v2 Launches: Revolutionizing DeFi Market Making with..
7/08/202309:03VWBritanniacoin’s Official Pre-release: introducing a unique..
7/06/202310:59VWTether Launches USDt On Kava
7/06/202303:03VWOKX to Launch Signal Trading Platform, Empowering Traders..

Your Recent History

NASDAQ
ALLO
Allogene Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved